Today, Brian Acker, CA and Gordon Reid commented about whether FDX-N, WBA-Q, URI-N, PFE-N, DY-N, TSLA-Q, FDX-N, LEN-N, DIS-N, SQ-N, GS-N, MS-N, QCOM-Q, CTB-N, VZ-N, BA-N, GE-N, CELG-Q, BAC-N, HD-N, MET-N, C-N, AAPL-Q, CSCO-Q, INTC-Q, BAC-N, TCL.A-T, CNQ-T, MSFT-Q, GOOG-Q, UA-N, DSG-T, MO-N, CNR-T, QCOM-Q, RCI.B-T, CAH-N, ENB-T, TECK.B-T are stocks to buy or sell.
He has owned this for years. His model price is $48.96. He believes in blockchain technology and this company will profit from it. Chinese competitors have a security issue disadvantage compared to this one. From all perspectives he thinks this is a great investment. Yield 3.0%. (Analysts’ price target is $48.42 )
Earnings season and the 10-year U.S. yield cracks 3%: The earnings were all that was advertised at 17%, though we're seeing 22% YOY increases so far. It's no secret that interest rates are rising, but how far? It's a psychological issue if investors think this bull run is over or not. There's a misconception among investors that things end, but they don't. There are weak and strong periods. How you manage the bad times defines you as an investor. It's easy to be an investor through the easy times. We value the upside more than the down, but the downside is the money-making side. He started in 2016-17 being strict with his asset mix including bonds and geographies, trimming his tech stocks last spring.
It's done well since fall 2016 when he bought it. It'll continue to do well. There's a misconception--the U.S. and Canadian banks don't need a positive yield curve to make money, though it helps. All they need are interest rates Iin general to go up. So, he sees a lot of runway for the banks, which won't rely on the yield curve to steepen.
A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.
He's been negative on this for a long time. It's a poorly run company with little credility left. Their cash flow is a mess. All their divisions are struggling. They've exited divisions that had some positive runway and went into areas that were struggling. It will continue to fall. The company may break up down the road.
He has a model price of $45.65 – 70% above current levels. This never trades where the fundamental value of the company is. It is near the upper range of historical value. He would look elsewhere.